Want to see SSKN full AI Analyst Report?
Top Page
Strata Skin Sciences
(OTC:SSKN)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.09
▼(-3.33% Downside)
Action:Reiterated
Date:10/09/26
The score is primarily driven by weak financial performance—ongoing losses, consistently negative free cash flow, and a balance sheet that has become more leveraged with reduced equity. Valuation is also constrained by negative earnings and no visible dividend support, while technical signals cannot be confirmed due to missing indicator data.
Positive Factors
Recurring Treatment Revenue
The in-office phototherapy model can create recurring, usage-linked revenue because patients typically receive a series of sessions. A growing installed base and higher practice utilization could therefore support repeat revenue beyond episodic device sales.
Negative Factors
Sharp Revenue Decline
The sharp 2025 revenue decline weakens confidence in near-term business momentum and may indicate difficulty expanding device placements, treatment volumes, or practice utilization. Persistent top-line contraction would also limit operating leverage and make recovery to profitability harder.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Treatment Revenue
The in-office phototherapy model can create recurring, usage-linked revenue because patients typically receive a series of sessions. A growing installed base and higher practice utilization could therefore support repeat revenue beyond episodic device sales.
Read all positive factors
Strata Skin Sciences (SSKN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.00
Dividend YieldN/A
Average Volume (3M)12.44K
Price to Earnings (P/E)―
Beta (1Y)34.87
Revenue Growth-8.54%
EPS Growth40.91%
CountryUS
Employees114
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.01
Shares Outstanding5,888,199
10 Day Avg. Volume364
30 Day Avg. Volume12,444
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)20.15
Price to Sales (P/S)1.91
P/FCF Ratio-13.75
Enterprise Value/Market Cap2.63M
Enterprise Value/Revenue0.51
Enterprise Value/Gross Profit0.89
Enterprise Value/Ebitda-27.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.29
Revenue Forecast (FY)$22.18M
Strata Skin Sciences Business Overview & Revenue Model
Company Description
STRATA Skin Sciences, Inc. is an innovative medical technology enterprise dedicated to the development, commercialization, and marketing of advanced products specifically designed for treating a range of dermatologic conditions. The company operat...
How the Company Makes Money
Strata Skin Sciences makes money primarily through (1) recurring usage-based/service revenues tied to in-office phototherapy delivered on Strata systems and (2) product-related revenues from selling and servicing its dermatology devices.
Key reve...
Strata Skin Sciences Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed sentiment. While there were significant advancements in the expansion of addressable markets and successful litigation outcomes, the overall financial performance was hampered by a decline in total and equipment revenue due to international trade challenges.Positive Updates
Expansion of CPT Codes
The historic expansion of CPT codes for STRATA's XTRAC 308-nanometer excimer laser, effective January 1, 2027, will expand reimbursement eligibility to include multiple inflammatory and autoimmune skin conditions, increasing the addressable market by threefold.
Negative Updates
Decline in Total Revenue
Total revenue for 2025 was $6.9 million, down 20% compared to 2024, mainly due to a challenging international environment.
Read all updates
Q3-2025 Updates
Positive
Negative
Expansion of CPT Codes
The historic expansion of CPT codes for STRATA's XTRAC 308-nanometer excimer laser, effective January 1, 2027, will expand reimbursement eligibility to include multiple inflammatory and autoimmune skin conditions, increasing the addressable market by threefold.
Read all positive updates
Company Guidance
During the call, STRATA Skin Sciences provided guidance and insights into their strategic initiatives and financial performance for the third quarter of 2025. A significant highlight was the anticipated expansion of CPT codes for the XTRAC 308-nanometer excimer laser, effective January 1, 2027, which is expected to significantly broaden reimbursement eligibility to over 30 skin conditions and potentially triple the addressable patient market. The company noted an 8.5% increase in average gross billings per device to $5,981, marking the highest since 2022, while recurring revenue saw a 4.1% growth. Despite total revenue falling 20% to $6.9 million due to international challenges, STRATA maintained a gross profit margin of 60%. The Elevate360 program, implemented in 99 clinics, resulted in a 7% growth for participating partners. Additionally, the company is focused on international expansion, with initial placements in Mexico, and is actively pursuing litigation against LaserOptik to reclaim market share, having already brought back approximately two dozen devices. STRATA remains optimistic about the fourth quarter and the long-term growth opportunities presented by expanded reimbursement and international market penetration.Strata Skin Sciences Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
24
Negative
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 30.70M | 33.56M | 33.36M | 36.16M | 29.98M |
| Gross Profit | 17.88M | 19.08M | 18.46M | 21.77M | 19.85M |
| EBITDA | 177.00K | -2.84M | -3.38M | 1.13M | 1.73M |
| Net Income | -6.26M | -10.09M | -10.83M | -5.55M | -2.71M |
Balance Sheet | |||||
| Total Assets | 30.52M | 36.16M | 42.02M | 52.27M | 46.59M |
| Cash, Cash Equivalents and Short-Term Investments | 7.91M | 7.26M | 6.78M | 5.43M | 12.59M |
| Total Debt | 16.27M | 16.44M | 15.63M | 8.44M | 8.03M |
| Total Liabilities | 27.61M | 31.18M | 29.33M | 30.44M | 21.18M |
| Stockholders Equity | 2.91M | 4.97M | 12.69M | 21.83M | 25.41M |
Cash Flow | |||||
| Free Cash Flow | -4.26M | -1.45M | -5.54M | -4.66M | -2.15M |
| Operating Cash Flow | -2.79M | 188.00K | -519.00K | -1.11M | 1.51M |
| Investing Cash Flow | -1.47M | -1.64M | -5.02M | -4.18M | -7.13M |
| Financing Cash Flow | 3.58M | 1.93M | 6.86M | -500.00K | 92.00K |
Strata Skin Sciences Risk Analysis
Strata Skin Sciences disclosed 45 risk factors in its most recent earnings report. Strata Skin Sciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Strata Skin Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $13.00M | -0.32 | -565.55% | ― | -28.53% | 47.55% | |
46 Neutral | $16.76M | -0.93 | -445.14% | ― | 8.64% | -61.01% | |
44 Neutral | $42.51M | -3.60 | -23.45% | ― | -14.27% | -132.84% | |
43 Neutral | $6.00 | ― | -268.41% | ― | -8.54% | 40.91% |
* Healthcare Sector Average
SSKN
Strata Skin Sciences
0.09
-1.61
-94.71%
SINT
Sintx Technologies
1.74
-1.72
-49.71%
CTSO
Cytosorbents
5.35
-11.49
-68.23%
XTNT
Xtant Medical Holdings
0.30
-0.47
-61.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.